One test: does the advertised price stay the same as you titrate to a higher dose? This is the same question as flat-rate pricing, viewed from the dose-escalation angle.
Among providers we reviewed, Henry Meds and NexLife advertise no dose-based increase (provider-stated), with Henry Meds at a lower flat rate. Fifty 410 is dose-tiered (price rises with dose). See the full flat-rate comparison.
The FDA resolved the tirzepatide (Dec 2024) and semaglutide (Feb 2025) shortages, and wind-down deadlines passed in 2025. On Apr 30, 2026 the FDA proposed excluding these drugs from the 503B bulks list (comment closed Jun 29, 2026). Patient-specific 503A compounding continues only narrowly, and cost alone is not a clinical need. Full regulatory status →
Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Primary source: FDA — Human Drug Compounding.